Planegg/Martinsried, February 19, 2025. (Medigene, FSE: MDG1, Prime Standard) Medigene AG, a leader in oncology focused on T cell receptor (TCR)-guided cancer therapies, announced a U.S. patent grant for its JOVI technology. This technology uses a specific anti-Cβ antibody to enrich T cells. The patent, granted late last year, was officially confirmed in 2025.

Dolores Schendel, Medigene’s CSO, stated that this U.S. patent, complementing their European patent, strengthens their comprehensive End-to-End (E2E) Platform and enhances their competitive advantage. Their expertise in T cell immunology enables the development of highly sensitive, specific, and safe (3S) TCRs for off-the-shelf TCR-guided T cell engager (TCR-TCE) and TCR-naked killer cell (TCR-NK) therapies.

Selecting optimal 3S TCRs is vital for creating safe and effective TCR-guided therapies. Medigene’s innovative JOVI technology uses a high-throughput method to enrich recombinant TCR-expressing T cells, allowing for efficient comparison of efficacy and safety profiles, leading to superior therapies.

Medigene continuously expands its patent portfolio by developing new 3S TCRs, integrating advanced technologies, and expanding its existing patents geographically. They now hold over 29 unique patent families globally, protecting their 3S TCRs and proprietary E2E Platform technologies.

—  end of press release  —

About Medigene AG

Medigene AG (FSE: MDG1) is an immuno-oncology platform company committed to developing effective TCR-guided therapies for cancer treatment. Their End-to-End Platform produces optimal 3S (sensitive, specific, and safe) T cell receptors for various therapeutic approaches, including off-the-shelf TCR-guided T cell engager (TCR-TCE) therapies (MDG3010), TCR-natural killer cell (TCR-NK) therapies, and TCR-engineered T cell (TCR-T) therapies (MDG1015). For more details, please visit 

This press release contains forward-looking statements reflecting Medigene’s current views. Actual results may differ significantly. Medigene is not obligated to update these statements. Medigene^® is a registered trademark of Medigene AG and may be owned or licensed in select locations only.

Medigene AG

Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com

To unsubscribe from Medigene communications, please email ().